ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mg
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington's Disease
Conditions
Huntington's Disease
Trial Timeline
Aug 6, 2015 → Nov 8, 2017
NCT ID
NCT02519036About ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mg
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mg is a phase 1/2 stage product being developed by Ionis Pharmaceuticals for Huntington's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02519036. Target conditions include Huntington's Disease.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02519036 | Phase 1/2 | Completed |
Competing Products
15 competing products in Huntington's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |
| BN82451B + Placebo | Ipsen | Phase 2 | 49 |
| WVE-120102 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| WVE-120101 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| SAGE-718 | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-718 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| OMS643762 + Placebo | Omeros Corporation | Phase 2 | 47 |
| VX15/2503 + Placebo | Vaccinex | Phase 2 | 44 |